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Background: This study aimed to evaluate the prophylactic effect of goshajinkigan (GJG) on paclitaxel (PTX)-induced
neuropathy and to elucidate the mechanism of action.
Results: There was a time-dependent irreversible decrease in pain threshold in PTX group. In PTX/GJG group, pain
threshold showed changes in the same level as control. Electron microscope showed that although the ganglion cells
of control and PTX/GJG groups were normal, degeneration of the nucleus and swelling of the mitochondria were
observed in PTX group. Expression of transient receptor potential vanilloid 4 (TRPV4) gene in PTX group significantly
increased compared with that in control and PTX/GJG groups. In TRPV4 knock-out mice, no PTX-induced hyperalgesia
was observed, and there was no significant difference in pain threshold between the 3 groups.
Conclusions: These results showed that PTX induced hyperalgesia by enhancing TRPV4 expression, and suggested that
GJG might alleviate hyperalgesia by preventing degeneration of the ganglion cells and suppressing TRPV4 expression.
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The combination of paclitaxel and carboplatin (TC ther-
apy) is the recommended standard chemotherapy follow-
ing a surgery for epithelial ovarian cancer [1]. In order to
reduce adverse effects during and after TC therapy, sup-
portive therapies for the digestive symptoms, myelosup-
pression, and hypersensitivity caused by anti-cancer drugs
have been invented and established [2-4]. However, mea-
sures against peripheral neuropathy (numbness) caused by
paclitaxel (PTX) remain unknown. The incidence of sen-
sory peripheral neuropathy in TC therapy was 78% [5], and
worsens the rate of treatment completion and reduces qual-
ity of life (QOL) of patients. Many attempts using NSAIDs,
steroids, antihistamines, tryptophan-N-formylated gramici-
din (NFG), glial cell-line derived neurotrophic factor
(GDNF), amifostine, gabapentin, and carbamazepine [6-8]* Correspondence: yokoyama@cc.hirosaki-u.ac.jp
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article, unless otherwise stated.have been conducted aiming to attenuate the drug-induced
peripheral neuropathy, however, no methods have been
established thus far.
Recently, the temperature-sensitive transient receptor
potential (TRP) channels are shown to be involved in
chemotherapy-induced neuropathic pain [9,10]. TRP chan-
nels are group of ion channel receptors located in the cell
membrane and form a large channel group consisting of 6
subfamilies and 28 channels in humans [11]. Since the dis-
covery of a temperature-sensitive TRP channel in 1997, 9
TRP channels were observed to be temperature-sensitive
[12]. Many TRP channels are present in various parts of the
body and play an important role as biological sensors for
receiving a number of chemical and physical stimulations
[13]. For example, TRPV1 is activated by stimulations of
heat, acid, capsaicin, and pain.
Goshajinkigan (GJG) is a traditional Japanese medicine,
comprising 10 types of crude drugs, rehmannia root, dis-
corea rhizome, cornus fruit, hoelen, alisma rhizome,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
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root, and plantago seed, and has been used for pain con-
trol in the lower extremities, numbness, blurred vision,
difficulty in urination, and edema [14]. GJG has been
shown to increase peripheral blood flow and exhibit anal-
gesic effects by increasing NO production [15], and is
shown to be effective for a treatment of numbness
caused by diabetes mellitus and cancer chemotherapy
[16], although the mechanism of action of GJG is un-
known. However, it has recently been suggested that
TRP channels are involved in the effect of GJG [17].
The present study aimed to clarify whether GJG is ef-
fective to reduce anti-cancer drugs induced neuropathy
and to elucidate its mechanisms in conjunction with TRP.
Results
Effect of GJG on mechanical allodynia in PTX-treated rats
The pain threshold in the PTX group showed a significant
decrease at the 1st week of PTX administration and stayed
at decreased levels even after PTX withdrawal, suggesting
that PTX increased the sensitivity to pain and that the ef-
fect of PTX last longer (Figure 1). The pain threshold of
PTX +GJG group, on the other hand, showed a temporally
decrease at 1st week of experiment but thereafter increased
and returned to similar levels of control groups, suggesting
that GJG prevented the effect of PTX on pain threshold
(Figure 1). From day 2 of administration of PTX, a signifi-
cant difference in the pain threshold between the PTX and
PTX +GJG groups was observed (Figure 1). The adminis-
tration of PTX and GJG did not result in adverse reactions
such as weight loss and self-harming.
Electron microscope findings in dorsal root ganglion cells
In comparison with the control group, there was clear
degeneration of the nucleus and swelling of the mito-
chondria in the PTX group, suggesting that PTX caused
neurodegenerative (Figure 2). In the PTX +GJG group,Figure 1 Comparison of the pain threshold. The pain threshold
was irreversibly decreased in PTX group. The pain threshold of the
PTX + GJG group was comparable with that of control group.
*P < 0.005, **P < 0.0001; PTX vs. PTX + GJG.however, there was no apparent degeneration of the nu-
cleus and swelling of the mitochondria and generally
showed cellular findings comparable with the control
group (Figure 2).
Screening of expression of TRP gene by DNA microarray
Gene expression of TRP subtypes in the DRG cells of the
control and PTX groups was compared using DNA micro-
array. A significant change was defined as the ratio of
change in expression ≥2 and the change value ≤0.05. How-
ever, out of the 15 types of TRP subtypes that could be ana-
lyzed, only TRPV4 showed a significant change (Figure 3A).
Validation of TRPV4 gene by RT-PCR
Gene expression of TRPV4 in the DRG, which showed a
significant change, was determined by TaqMan Gene Ex-
pression Assay. PTX group showed significant increase in
TRPV4 compared with the control and PTX +GJG groups
(Figure 3B). In contrast, the results showed that co-
administration of GJG significantly decreased gene expres-
sion of TRPV4 (Figure 3B).
Comparison of protein expression of TRPV4 in the DRG
When the protein expression of TRPV4 in the DRG was
analyzed using Western blot through signal density, the
PTX group showed a significant increase compared with
the control group (Figure 4A, P < 0.05), and the expression
of TRPV4 was significantly suppressed in the PTX +GJG
group compared with the PTX group (Figure 4A, P <
0.01). Moreover, when the expression of TRPV4 in DRG
cells was classified into negative, weakly positive, and
strongly positive, it was confirmed that the expression
of TRPV4 in the DRG cells was significantly increased
in the PTX group compared with that in the control
group (Figure 4B, P < 0.005) and significantly sup-
pressed in the PTX + GJG group (Figure 4B, P < 0.01).
Comparison of the expression of TRPV4, integrin, and Src
tyrosine kinase using tissue microarray
For TRPV4 to intracellularly communicate sensory stim-
ulations, it is essential for integrin and Src tyrosine kin-
ase to bind to the stimulation receptor TRPV4. Thus,
the expressions of TRPV4, integrin, and Src tyrosine kin-
ase in the DRG were simultaneously compared using tis-
sue microarray. In the PTX group, TRPV4, integrin, and
Src tyrosine kinase were more strongly expressed in the
nucleus, cytoplasm, and cell membrane of the ganglion
cells compared with the control group (Figure 5). A char-
acteristic finding in the PTX+GJG group was that the ex-
pression of TRPV4 in the nucleus and cytoplasm was
clearly decreased compared with that in the PTX group
(Figure 5). Meanwhile, between the PTX group and
PTX + GJG groups, no clear change in expression was
found in Src tyrosine kinase and integrin (Figure 5).
Figure 2 Electron microscope findings of the dorsal root ganglion cell. A. Control, magnification of 1000×. B. PTX, magnification of 1500×.
C. PTX + GJG, magnification of 1000×.
Figure 3 Altered expression of TRP genes by paclitaxel.
A. Screening of expression of TRP genes by DNA microarray.
B. TRPV4 validaton by RT-PCR. TRPV4 gene, whose change in expression
was significant in DNA microarray, was determined by TaqMan Gene
Expression Assay. †P < 0.001, vs. control. §P < 0.005, vs. PTX +GJG.
‡P = 0.05, vs. control.
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knock-out mice
There was no decrease in pain threshold following the ad-
ministration of PTX. There was no significant difference
in the pain threshold between the 3 groups (Figure 6).
Discussion
This study showed that the administration of PTX
caused a significant and irreversible decrease in pain
threshold (increase in hyperalgesia), and that administra-
tion of GJG blocked the effect of PTX. PTX is a mitotic
inhibitor used for cancer chemotherapy as it acts by tar-
geting the microtubules necessary for the transport of chro-
mosomes during cell division [18]. It has been reported in
the PTX-induced pain model that PTX treatment causes
changes in nerve axon diameter, disorientation of microtu-
bules, and mitochondrial swelling [19]. The result of the
present study has confirmed electron-microscopically that
PTX administration induced neural degeneration such as
the nucleus and mitochondrial swelling in the DRG cells.
In addition, present study showed for the first time that
GJG administration decreases pain threshold by protecting
the nerve cells from degeneration.
TRP channels are group of ion channel receptors located
in the cell membrane and form a large channel group con-
sisting of 6 subfamilies and 28 channels in humans [11].
Many TRP channels are present in various parts of the
body and play an important role as biological sensors for
receiving a number of chemical and physical stimulations
[13]. Kato et al. have shown that oxaliplatin caused hyper-
sensitivity to cold sensation and that GJG reduced then
oxaliplatin-induced hypersensitivity and its effect would be
related to suppression of the expression of TRPM8 and
Figure 4 Comparison of protein expression of TRPV4 in the dorsal root ganglions. A. Comparison of the expression of TRPV4 by Western blot.
Expression of TRPV4 was significantly increased in the PTX group and significantly suppressed by the co-administration of GJG. The experiment was
repeated 3 times, and the means were expressed numerically. The figures shown are representative photographs. †P < 0.05, vs. control. ‡P < 0.01, vs.
PTX + GJG. B. Comparison of the expression of TRPV4 by immunohistochemistry. The expression of TRPV4 in ganglion cell was classified into negative,
weakly positive, and strongly positive, as shown in the figure and the level of TRPV4 expression between the 3 groups was compared. *P < 0.005,
**P < 0.01.
Figure 5 Comparison of the expressions of TRPV4, integrin, and Src tyrosine kinase by tissue microarray. In PTX group, TRPV4, integrin,
and Src tyrosine kinase were more strongly expressed in the nucleus, cytoplasm, and cell membrane in ganglion cell compared with the control
group. In PTX + GJG group, no clear change in the expression of Src tyrosine kinase and integrin was noted, but the expression of TRPV4 in the
nucleus and cytoplasm was clearly decreased compared with PTX group.
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Figure 6 PTX-induced shift in the pain threshold in TRPV4
knock-out mice. PTX did not induce hyperalgesia, and there was no
significant difference in the pain threshold between the 3 groups.
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however, the present study has shown that TRPV4 was in-
volved in PTX-induced hyperalgesia. TRPV4 is a molecule
widely involved in the development of neuropathic pain
[20] and elicits its action through formation of a complex
with integrin or Src tyrosine kinase [20]. In general, it is
said that TRPV4 was mainly distributed in the skin but a
little in the sensory nerves [21]. However, the present study
clearly demonstrated that TRPV4 is present in sensory
nerves and is induced in the DRG cells in response to ad-
ministration of PTX. In addition, integrin and Src tyrosine
kinase also expressed at high levels in response to adminis-
tration of PTX, strongly suggesting that TRPV4 in DRG
cells is involved in PTX-induced hypersensitivity to pain
sensation. As shown in Figure 6, TRPV4 knock-out mice
did not show any decrease in pain threshold as a result of
PTX administration, confirming that TRPV4 is involved in
PTX-induced hyperalgesia. In addition, induction of TRPV4
and its complex with integrin and Src tyrosine kinase
showed no apparent increase upon co-administration with
GJG, suggesting that the action of GJG is to suppress the
expression of TRPV4, integrin and Src tyrosine kinase
complex.
GJG is a compound consisting from 10 components
and each component has its own pharmacologic action
[22-24], but it is thought that co-administration of 10
components exerts most suitable effects as a clinical
regimen. Indeed, it is shown that GJG is effective
against “numbness” caused by diabetic neuropathy [14].
In addition, laboratory studies have shown that GJG ex-
erts many pharmacological effects. For example, GJG
suppresses the release of pain-transmitting substance,
increases NO production mediated by bradykinin B2 re-
ceptor and muscarinic acetylcholine receptor [15] and
reduces reactive oxygen species production [25]. Be-
cause PTX therapy accumulates of hydrogen peroxide
[26,27] and antioxidant such as N-acetylcysteine can
alter the cytotoxicity of PTX [28] and PTX-inducedmechanical hyperalgesia [29], it is presumed that anti-
oxidant action of GJG is likely be involved in protecting
PTX-inducing neural damage. Materazzi et al. demon-
strated that an antioxidant, glutathione, suppresses
PTX-induced expression of TRPV4 in the sensory nerve
[30], which strongly supports our presumption.
In thermoregulatory system, one of the ion channel
receptors called TRPM8 plays an important role [31].
Peripheral hypersensitivity to cold sensations is com-
monly associated with oxaliplatin-induced peripheral
neurotoxicity, and possible involvement of TRPM8 is
demonstrated [32]. Of interest, Ushio et al. showed in
oxaliplatin-treated animals that GJG reduced hypersen-
sitivity to cold stimulation but not hypersensitivity to
mechanical stimulation [33]. As shown in Figure 3A, we
could not find any significant change in TRPM8 gene
expression in PTX administration, suggesting that oxali-
platin and PTX elicit neurotoxicity in a different manner.
Nevertheless, the fact that GJG could reduce the neuro-
toxicity caused by oxaliplatin and PTX may suggest that
GJG is useful for anti-cancer-drug induced neuropathy in
clinical practice. Indeed, the efficacy of GJG on peripheral
neuropathy has been accumulated in clinical studies on
patients receiving chemotherapies [16,34,35].
In a clinical study on PTX for ovarian and endometrial
cancer in patients with peripheral neuropathy, GJG was
observed to stop the progression of peripheral neur-
opathy to a certain degree, but there was no clear im-
provement in symptoms compared with that in the
control group [35]. As it is apparent from this study,
hyperalgesia occurred in the early stages of administration
of PTX and caused irreversible changes in rats. In this
study, PTX-induced peripheral neuropathy could be pre-
vented by administering GJG prior to the administration
of PTX. It is possible that irreversible peripheral neur-
opathy also occurs in humans in early stages of adminis-
tration of PTX. When verifying the prophylactic effects of
GJG against PTX-induced peripheral neuropathy, it is ad-
visable that the clinical study is designed to administer
GJG prior to the administration of PTX.
Methods
Animals
The animal experiments were conducted in accordance
with the Guidelines for Animal Experimentation, Hirosaki
University and the guidelines of the International Asso-
ciation for the Study of Pain. Eight-week-old female
Fisher344 rats weighting 180–200 g and Trpv4−/− mice
[36,37] weighting 20–25 g were used in this study. They
were group-housed in plastic cages with stainless-steel
grid tops and kept in an air-conditioned room maintained
at 22 ± 2°C in the Institute for Animal Experiments of
Hirosaki University. Artificial light was provided on 12-
hour cycle. They had free access to food and water.
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administration
PTX was obtained from Nippon Kayaku (Tokyo, Japan).
PTX was diluted with sterile saline and injected intraperito-
neally (i.p.) at a dose of 10 mg/kg per a week for three
weeks to establish a rodent model presenting PTX-induced
neuropathy [38]. GJG was obtained from TSUMURA &
Co. (Tokyo, Japan). GJG was diluted with distilled water.
The experimental rodents were divided into three
groups containing 5 rodents each. Control group re-
ceived basal diet alone. PTX group was administered
PTX at 10 mg/kg i.p. by the method mentioned above.
The combination of GJG and PTX treatment group
(PTX +GJG group) was given GJG into the esophagus
through a per os gastric tube at a dose of 150 mg/kg
once a day for 5 weeks from a week before PTX admin-
istration and was given paclitaxel in the same way as ad-
ministered for PTX group. The single dose of GJG
administered to the rodents conforms to that at which a
patient weighing 50 kg is given per a day.
Behavioral analysis
Behavioral tests were done in a quiet, temperature-
controlled room between 1 p.m. and 4 p.m. and were
carried out by an inspector who was not informed of
treatment group. PTX-induced mechanical allodynia and
hyperalgesia were measured with an automated von Frey
testing device, a dynamic plantar esthesiometer (Ugo
Basile, Italy). Rodents were placed in clear plastic box
(110 × 180 × 140 mm) on wire mesh floor and allowed to
acclimatize for 1 hour. The touch-stimulator was moved
below the rodent right hind paw. The actuator filament
(0.5 mm diameter) moved upward increasing force
(force increasing rate: 5 g/s, over a 20 s period) until the
rodents removed their paw. When the paw was with-
drawn, the actuator moving was stopped and the device
was recorded the force at which the rodent withdrew its
paw. The examination was performed once before PTX
administration (baseline), the second day after PTX ad-
ministration and every week after PTX withdrawal.
Stimulation to a rodent was applied three times at 1-2-
min interval, and the average was calculated.
Isolation of primary sensory neurons
The rats of each group were sacrificed with a high dose
of i.p. sodium pentobarbital (200 mg/kg) on Day 35 after
PTX administration, and dorsal root ganglia (DRG) was
removed for pathological, molecular and biochemical
studies. The lumbar DRG (L4 and 5) were bilaterally ex-
cised under a dissection microscope.
Electron microscopy
The excised DRG were fixed in 2.5% glutaraldehyde so-
lution, washed with 7.5% sucrose for 10 min, post-fixedfor 2 hours in 1% osmium tetroxide, and after washed
with 50% ethanol, dehydration was done continuously
through a graded ethanol series. After substitution from
ethanol to QY-1 (Okenshoji Co., Ltd, Tokyo, Japan), these
specimens were embedded in epoxy resin (TAAB Labora-
tories Equipment Ltd, Berkshire, UK) and ultra-thin sec-
tions (80–100 nm) were collected on copper grids by
using Ultratome® NOVA (LKB, Bromma, Sweden).
Double-staining was done with uranyl acetate (for 20 min)
followed by lead citrate (for 10 min). Finally, these speci-
mens were examined and photographed with JEM 1010
(JEOL, Tokyo, Japan) equipped with Orius® SC200 CCD
camera (Gatan, CA) for transmission electron microscopy
at 80 kV of acceleration voltage.
Total RNA isolation
Tissues were first homogenized by homogenizer and
then by the TRIzol reagent (Invitrogen Life Technolo-
gies, Carlsbad, CA) for the total RNA extraction follow-
ing the manufacturer’s instructions. The extracted total
RNA was then purified using the RNeasy MiniElute
Cleanup Kit column (Qiagen, Tokyo, Japan) with the
DNase incubation (Qiagen). Total RNA extracted was
quantified using an Eppendorf UV spectrophotometer,
and the integrity of the RNA samples was controlled
using Agilent 2100 Bioanalyzer (Agilent Technologies
Inc, Palo Alto, CA) with the NanoDrop ND-1000 Kit
(Thermo Fisher Scientific Inc., Waltham, MA). Only
RNAs with OD260/OD280 > 1.8 and an RNA integrity
number (RIN) > 7 were used for microarray experiments.
The remaining good-quality RNAs were kept for the
subsequent RT-PCR confirmative experiments.Microarray analyses
Each good-quality sample was hybridized to the Affyme-
trix HG-U133 plus 2.0 GeneChip (Affymetrix, Santa
Clara, CA). This gene chip analyzes the expression level
of 38,500 well-characterized human genes. First, 10 μg
of the total RNA was reverse-transcribed with the Super-
Script Choice System (Invitrogen) with oligo dT primers
containing a T7 RNA polymerase promoter site. Then,
cDNA was in vitro transcribed and labeled with biotin
using the IVT labeling kit (Affymetrix) followed by the
fragmentation of the biotinylated cRNA. Next, the qual-
ity of this cRNA was assessed with the Agilent 2100 Bioa-
nalyzer. The fragmented cRNA was hybridized overnight
to Affymetrix Human Genome U133APlus 2.0 Arrays and
scanned following the guidelines. The chips were washed
and stained using the GeneChip Fluidics Station 400
(Affymetrix) and then scanned with the GeneChip Scan-
ner 3000 (Affymetrix). The ratio from signal intensity
values of four time points was calculated. Pathways regu-
lated at p < 0.05 were considered significant.
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Quantitative PCR (qPCR) was utilized to evaluate gene
expression of Trpv4. TaqMan® Gene Expression Assays
(Life Technologies, Forester City, CA) was used for assay:
TaqMan® probes of Trpv4 (Rn00583117_m1) and Actb
(Rn00667869_m1) were used. Primers used for PCR were
as follows: TRPV4, 5′-ACCAGTACTATGGCTTCTCC-3′
and 5′-AATTCCCTACTCTACCCTGC-3′. Actb, 5′-AG
TCCCTTGCCATCCTAAAAGC-3′ and 5′-GGGAGAGG
ACTGGGCCATT-3′. Before qPCR, reverse transcription
of 500 ng of total RNA was performed using SuperscriptR
VILO® cDNA synthesis kit (Life Technologies), qPCR re-
actions were set-up in 20 μl volumes with 50-fold cDNA
dilutions, 20× TaqMan® gene expression assay mix, 2×
TaqMan® Universal PCR master mix II (Life Technolo-
gies), and dH2O. PCRs were performed in quadruplicate
following the manufacture protocols on an model ABI
Prism 7000 real-time PCR system (Life Technologies)
using the following protocol: an initial denaturation and
polymerase activation step for 10 min at 95°C, followed by
40 cycles of denaturation at 95°C for 15 s and 60°C for
1 min. Actb was used as a reference gene to normalize
between samples.
Western blot analyses
Removed DRG tissues were homogenized in PIPA buffer
in ice. The homogenate was incubated overnight at 4°C
followed by centrifuging at 15000 g for 15 min at 4°C.
The supernatant fluids (50 μg protein) were electropho-
resed through a 10% sodium dodecyl sulfate (SDS)-poly-
acrylamide gel and blotted as described previously [39].
The protein concentration was determined using the
Bradford method. The blots were probed with following
primary antibodies; TRPV4 (Alomone Labs, Jerusalem,
Israel) at 1:200 or β-actin (Sigma-Aldrich, St Louis, MO)
at 1:1000. The membranes probed by TRPV4 was incu-
bated for 2 hours with anti-rabbit immunoglobulin and
transferred to the avidin-biotinylated enzyme complex
(VECTA Laboratories, Burlingame, CA) for 30 min. Di-
aminobenzidine (DAB) (Sigma-Aldrich) was used as the
substrate. The membrane probed by β-actin was incu-
bated for 1 hour with anti-mouse immunoglobulin. Quan-
tification of the results was performed by scanning the
membrane with Photoshop software (version 5.5, Adobe
Systems) followed by densitometry with the public domain
software, NIH Image, version 1.62.
Immunohistochemical analyses
Six-μm sections of formalin-fixed and paraffin-embedded
tissue specimens were stained by established method as
described previously [39]. Sections were routinely passed
through xylen and a graded alcohol and were blocked en-
dogenous peroxidase activity by incubating sections in 3%
H2O2 solutions in methanol. Sections were incubated withblocking buffer (VECTA Laboratories) for 20 min and
were reacted with Anti-TRPV4 (Alomone Labs, 1:1000)
for 30 min in a humidified chamber at room temperature.
Next, Sections were added a biotin-labeled secondary anti-
body which was biotinylated anti-rabbit IgG and were in-
cubated with the avidin-biotinylated enzyme complex
(VECTA Laboratories) for 30 min. The binding sites of
peroxidase were determined using DAB as the substrate.
Sections were then counterstained with hematoxylin for
microscopic examinations. 2 observers (Y.Y. and H.H.) in-
dependently evaluated and interpreted the results of
immnohistochemical staining. Interpretation of the immu-
nohistochemical staining was classified into three categor-
ies based on staining intensity (negative, weekly positive,
or strongly positive).
Tissue microarray
For the tissue microarray (TMA), hematoxylin and
eosin- stained sections were used to define the ganglion
cells and preserved DRG from the rats used in this ex-
periment. One ganglion representative 3 mm core was
obtained from each rat and inserted in a grid pattern
into a recipient paraffin block using a tissue arrayer (JF-
4 Pathology Institute Corp, Toyama, Japan). Sections
(2 μm) were then cut from each TMA block and stained
imuunohistochemically with anti-TRRV4 (Alomone Labs,
1:1000), anti-integrin (Alomone Labs, 1:200) and ant-Src
tyrosine kinase (Epitomics Inc. Burlingame, CA, 1:250).
TRPV4 knockout mice
Trpv4−/− mice were generated with a C57BL/6 back-
ground as described previously [36,37]. Adult mice from
generations N8-N10 were used in this study. They were
divided into three groups containing 5 mice each. PTX-
induced mechanical allodynia and hyperalgesia were
compared among the 3 groups of control, PTX, and
PTX +GJG. PTX and GJG were given in the same way
as mentioned above.
Statistical analysis
Statistical analyses were carried out by Student’s t-test,
Chi square test or Fisher’s exact probability test. A result
was deemed significant at P < 0.05.
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